Observational studyVascular health and risk management2020
Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study.
Observational study in Vascular health and risk management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Deep Vein Thrombosis Prevention in Acute Ischemic Stroke Patients with Lower Limb Paralysis: A Narrative Review.Journal of clinical medicine · 2026Review
- A prospective cohort study on prognostic implications of serum platelet derived microparticles levels in acute cerebral infarction.Scientific reports · 2025Article
- Metabolic landscape in venous thrombosis: insights into molecular biology and therapeutic implications.Annals of medicine · 2024Review
- Preliminary clinical analysis and pathway study of S100A8 as a biomarker for the diagnosis of acute deep vein thrombosis.Scientific reports · 2024Article
- Platelet-derived microparticles and their cargos: The past, present and future.Asian journal of pharmaceutical sciences · 2024Review
- Extracellular vesicles in venous thromboembolism and pulmonary hypertension.Journal of nanobiotechnology · 2023Review
- Hemostatic In Vitro Properties of Novel Plasma Supernatants Produced from Late-storage Low-titer Type O Whole Blood.Anesthesiology · 2023Article
- Platelet-Derived Microparticles and Autoimmune Diseases.International journal of molecular sciences · 2023Review
- Platelets at the Vessel Wall in Non-Thrombotic Disease.Circulation research · 2023Review
- Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe role of platelets (Ps) and platelet-derived microparticles (MPs) in venous thromboembolism (VTE) is still being debated.
methodsWe measured MPs, velocity of thrombin formation (PiCT) and phospholipid generation (PLPs) in 40 patients with unprovoked deep vein thrombosis (DVT), who were compared with 40 healthy controls.
resultsMPs were higher in DVT (7.12 nM; 25th-75th percentile 5.26-9.12) than in controls (5.45 nM; 25th-75th percentile 1.67-8.96) (p = 0.19). PiCT velocity was lower in DVT (1.87 sec; 25th-75th percentile 1.75-1.93 sec) compared with controls (1.95 sec; 25th-75th percentile 1.84-2.24 sec) (p = 0.04). PLPs were higher in DVT (77.03 µg/mL; 25th-75th percentile 72.12-103.59 µg/mL) compared with controls (68.65 µg/mL, 25th-75th percentile 55.31-78.20 µg/mL) (p = 0.02). DISCUSSION: We hypothesize that MPs could be integrated with the lab network assay in evaluating Ps' role as an activated procoagulative condition. We encourage research on Ps and P-derived microvesicle pathways in patients with unprovoked DVT and not only in patients with cancer-induced DVT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.